nab sirolimus advanced malignant perivascular epithelioid cell tumors aABI 009NAB Sirolimus在晚期恶性周围上皮细胞肿瘤中.pptx

ABI-009(nab-sirolimus)inAdvancedMalignantPerivascularEpithelioidCellTumors(PEComa):PreliminaryEfficacy,Safety,andMutationalStatusfromAMPECT,anOpen-labelPhase2RegistrationTrialPresentedByAndrewWagnerat2019ASCOAnnualMeeting

DisclosuresPresentedByAndrewWagnerat2019ASCOAnnualMeeting

MalignantPerivascularEpithelioidCelltumor(PEComa)PresentedByAndrewWagnerat2019ASCOAnnualMeeting

ABI-009(nab-Sirolimus)PresentedByAndrewWagnerat2019ASCOAnnualMeeting

AMPECT:nab-SirolimusinAdvancedMalignantPEComabr/Phase2RegistrationalOpen-labelMulticenterStudyDesignPresentedByAndrewWagnerat2019ASCOAnnualMeeting

BaselineDemographicsandCharacteristicsbr/Enrollmentisclosed,studyisongoingPresentedByAndrewWagnerat2019ASCOAnnualMeeting

SafetySummary,Treatment-relatedAdverseEventsPresentedByAndrewWagnerat2019ASCOAnnualMeeting

Slide8PresentedByAndrewWagnerat2019ASCOAnnualMeeting

Responsetonab-SirolimusPresentedByAndrewWagnerat2019ASCOAnnualMeeting

Responsetonab-SirolimusPresentedByAndrewWagnerat2019ASCOAnnualMeeting

DurationofResponse,TimetoResponse,br/Progression-freeSurvivalPresentedByAndrewWagnerat2019ASCOAnnualMeeting

MutationalAnalysisandBiomarkersbr/EfficacyvsTSC1/TSC2mutations/deletionsbyNGSandpS6byIHCPresentedByAndrewWagnerat2019ASCOAnnualMeeting

PreliminaryResultsofRegistrationaltrial:AMPECTbr/nab-SirolimusinAdvancedMalignantPEComabr/ConclusionsPresentedByAndrewWagnerat2019ASCOAnnualMeeting

Thankyoutothepatientsandfamilies,andtothestudyteams!PresentedByAndrewWagnerat2019ASCOAnnualMeeting